bat8008
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05620017)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TACSTD2 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06341114 | Phase 1/Phase 2 (Phase 2) | Apr 12, 2024 | Biothera |
| NCT05620017 | Phase 1 | Nov 30, 2022 | Biothera, Sun Yat-Sen University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biothera | For profit | 2 | 2 | 2 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1